In a transformational period since its April 2015 IPO on AIM, Motif Bio plc has made significant progress in advancing its late clinical-stage antibiotic programme. Motif is now pursuing a NASDAQ listing in preparation for the drug’s future US launch. We believe that a US listing could help bridge the significant valuation gap between Motif and its US peers. In the wake of a major antibiotic resistance crisis, the treatment’s sales could run into billions of US dollars per year.
27 Jul 2016
A transformational period
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A transformational period
- Published:
27 Jul 2016 -
Author:
Vadim Alexandre -
Pages:
16
In a transformational period since its April 2015 IPO on AIM, Motif Bio plc has made significant progress in advancing its late clinical-stage antibiotic programme. Motif is now pursuing a NASDAQ listing in preparation for the drug’s future US launch. We believe that a US listing could help bridge the significant valuation gap between Motif and its US peers. In the wake of a major antibiotic resistance crisis, the treatment’s sales could run into billions of US dollars per year.